Trastuzumab deruxtecan (also known as T-DXd and DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload ...

progression were reduced with administration of trastuzumab deruxtecan vs trastuzumab emtansine, according to findings of a DESTINY-Breast03 trial interim data analysis published today in the New ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine ...

Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients ...

substituting trastuzumab emtansine for adjuvant trastuzumab is associated with a reduced risk for invasive recurrence of human epidermal growth factor receptor 2-positive primary breast cancer.

The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast ...

More information: Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer, New England Journal of ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab ...

Up-to-date prescription details regarding Ado-trastuzumab Emtansine are provided here. Understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take ...

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine , 2025; 392 (3): 249 DOI: 10.1056/NEJMoa2406070 Cite This Page : ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...